JoyMed Technology

About JoyMed Technology

JoyMed Technology, established in Shanghai in 2014 by founder and CEO Jeffrey Cao, operates as a contract design and manufacturing organization (CDMO) for the medical device industry. The firm provides comprehensive, one-stop services to a global client base of medical device manufacturers, biopharmaceutical companies, and clinical institutions. Its business model is centered on offering outsourced solutions that span the entire product lifecycle, from initial concept and design through regulatory compliance, contract manufacturing, and post-market services. This approach is designed to help clients accelerate product launches, manage costs, and ensure regulatory adherence without JoyMed developing its own branded products, thereby protecting client intellectual property.

The company's service portfolio is extensive, covering product design and development, risk management, product verification and validation, and registration. JoyMed specializes in contract manufacturing (CMO), regulatory and registration consulting (CRO), and provides services for Class I, II, and III medical devices. Its expertise encompasses various product categories, including drug delivery systems, diagnostic and life science equipment, cardiovascular and oncology treatment devices, and interventional consumables. The company has built significant capabilities in precision injection molding and tube extrusion, supporting the production of both active and sterile medical devices.

Since its founding, JoyMed Technology has achieved several key milestones, reflecting its strategic growth. The company has secured substantial venture capital funding through multiple rounds, including a Series A in 2018, Series B in 2021, and a Series B1 in 2022, attracting investors such as CICC Capital, Legend Capital, and YuanBio Venture Capital. This financial backing has fueled its expansion, which includes establishing a global footprint with its head office for development in Shanghai, CDMO facilities in Suzhou and Changsha, a specialized molding and extrusion plant in Changzhou, and a high-level assembly and testing facility in Singapore, which opened in 2023. The firm employs over 300 people, with a significant portion of its technical team having extensive experience from international medical device companies.